Non-Small Cell Lung Cancer

Filter By:
http://cance... Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant. GRACEcast 250 Lung
by:cancergrace | 49 views
http://cance... The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results. GRACEcast 248 Lung
by:cancergrace | 130 views
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases. GRACEcast 246 Lung
by:cancergrace | 127 views
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab). GRACEcast 244 Lung
by:cancergrace | 164 views
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients. GRACEcast 242 Lung
by:cancergrace | 193 views
http://cance... Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some. GRACEcast 240 Lung
by:cancergrace | 156 views
This series of interviews with eight expert faculty is filmed on location during the 2014 American Society of Clinical Oncology (ASCO) Annual meeting, where the most current cancer data is presented and examined. Following the scientific sessions, Dr. James Epstein reviews and explores some of the most significant research findings in multiple tumo...
by:imedex | 272 views
http://cance... EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial. GRACEcast 237 Lung
by:cancergrace | 152 views
http://cance... An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer. GRACEcast 236 Lung
by:cancergrace | 206 views
http://cance... Progression-fre​e survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival? GRACEcast 235 Lung
by:cancergrace | 245 views

Top Tags

Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Different type of MD 
Other oncology Professional 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.

username:   password: remember me

Sign In

Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)